Novo Nordisk Partners With Vivani on Twice-a-Year GLP-1 Implant to Fight Weight Regain
Novo Nordisk has struck a deal with biotech Vivani Medical to test a semaglutide implant meant to keep patients on GLP-1 therapy long term instead of quitting the shots. The device is years from approval, and doctors say they need real trial data before believing it solves the drug's biggest problem: people stopping.